What is the price-to-earnings ratio of Incyte?
The price-earnings ratio of Incyte is currently 51.77.
Incyte P/E 2024
Incyte P/E
51.77
Ticker
INCY
ISIN
US45337C1027
WKN
896133
As of Dec 18, 2024, Incyte's P/E ratio was 51.77, a 122.67% change from the 23.25 P/E ratio recorded in the previous year.
The Incyte P/E history
Incyte Aktienanalyse
What does Incyte do?
The Incyte Corporation is a global biotechnology company specializing in the research and development of drugs for the treatment of cancer and other serious diseases. Incyte was founded in 1991 in Delaware, USA, by Roy Whitfield, a biotech entrepreneur, with the aim of finding new approaches to drug discovery. The company initially focused on developing DNA sequencing technologies and building an extensive database for drug identification. Over the years, Incyte expanded its expertise in genomics research and collaborated with pharmaceutical companies to develop new medications. In 2002, Incyte entered into a strategic alliance with Eli Lilly and Company to jointly research drugs for cancer and other diseases. Today, Incyte offers a wide range of medications for the treatment of cancer, immune and inflammatory disorders, and rare genetic diseases. The company's business model is based on the discovery and development of new drugs, utilizing its strengths in genomics research and biomarker development to identify and develop targeted therapies. Incyte has also increasingly focused on the development of immunotherapies, particularly antibodies targeting cancer and other diseases by activating the immune system. The company has positioned itself as a leading provider of genetic tests for rare diseases in the United States, offering a broad range of diagnostic tests based on genetic mutations. Incyte is a rapidly growing company with a strong emphasis on innovation and research. It has a strong presence in the field of cancer therapy and is working to expand its expertise in immunology and genomics research. Incyte is considered a promising candidate for future growth and success in drug development in the biotech industry. Incyte ist eines der beliebtesten Unternehmen auf Eulerpool.com.Incyte revenue by segment
82 % Product
14 % Product Royalty
4 % Milestone & Contract
P/E Details
Deciphering Incyte's P/E Ratio
The Price to Earnings (P/E) Ratio of Incyte is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.
Year-to-Year Comparison
Assessing Incyte's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.
Impact on Investments
The P/E ratio of Incyte is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.
Interpreting P/E Ratio Fluctuations
Fluctuations in Incyte’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.
Frequently Asked Questions about Incyte stock
How has the price-earnings ratio of Incyte changed compared to last year?
The price-to-earnings ratio of Incyte has increased by 122.67% increased compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Incyte high compared to other companies?
Yes, the price-to-earnings ratio of Incyte is high compared to other companies.
How does an increase in the price-earnings ratio of Incyte affect the company?
An increase in the price-earnings ratio of Incyte would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Incyte affect the company?
A decrease in the price-earnings ratio of Incyte would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Incyte?
Some factors that influence the price-earnings ratio of Incyte are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Incyte pay?
Over the past 12 months, Incyte paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Incyte is expected to pay a dividend of 0 USD.
What is the dividend yield of Incyte?
The current dividend yield of Incyte is .
When does Incyte pay dividends?
Incyte pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Incyte?
Incyte paid dividends every year for the past 0 years.
What is the dividend of Incyte?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Incyte located?
Incyte is assigned to the 'Health' sector.
Wann musste ich die Aktien von Incyte kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Incyte from 12/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.
When did Incyte pay the last dividend?
The last dividend was paid out on 12/18/2024.
What was the dividend of Incyte in the year 2023?
In the year 2023, Incyte distributed 0 USD as dividends.
In which currency does Incyte pay out the dividend?
The dividends of Incyte are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Incyte stock can be added to a savings plan with the following providers: Trade Republic and Consorsbank
Andere Kennzahlen von Incyte
Our stock analysis for Incyte Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Incyte Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
